Shilkrut M, et al. - Researchers have previously demonstrated that moderate doses of chemoradiotherapy can elicit a response in patients with refractory neuroendocrine tumors. In a dose-escalation phase I/II trial combining hepatic arterial (HA) chemotherapy, chemoembolization, and dose-escalated whole liver radiotherapy, they looked for the maximum safe dose of radiation that could be delivered and to make a preliminary assessment of response. It was found safe to deliver thirty-two in 2 Gy daily fractions in combination with HA chemotherapy and subsequent transarterial chemoembolization. Despite objective responses, this combination was not significantly better than the prior approaches.